HCGHealthcare Global Enterprises Ltd.
Healthcare Global Enterprises Q2 FY27 Results: Consolidated Net Profit ₹9.25 Crore on Total Income of ₹734 Crore
- Earnings
- Healthcare services
Reviewed byKeshav SehgalBlacklitt Research
Healthcare Global Enterprises (NSE: HCG) reported consolidated total income of ₹733.71 crore and a consolidated net profit of ₹9.25 crore for the quarter ended 30 Sep 2026, it said in a filing on 05 Nov 2026. Standalone total income was ₹401.35 crore and the standalone result was a net loss of ₹2.04 crore.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹733.71 crore, up 13.0% YoY and 3.7% QoQ
- Net profit: ₹9.25 crore, down 55.2% YoY and 43.8% QoQ
- EPS: Basic ₹0.32, against ₹1.15 a year earlier
- Exceptional item: ₹11.59 crore provision for EPCG customs duty and interest
Standalone
The company on its own, without its subsidiaries
- Total income: ₹401.35 crore, up 14.8% YoY and 3.9% QoQ
- Net loss: ₹2.04 crore, against a profit of ₹10.78 crore a year earlier
- EPS: Basic loss of ₹0.14 per share
- Exceptional item: ₹6.61 crore EPCG customs duty provision
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 734 | 649 | +13.0% | 707 | +3.7% | |
| Revenue from operations | 730 | 645 | +13.2% | 693 | +5.3% |
| Other income | 2 | 3 | -27.1% | 12 | -84.3% |
| 9 | 21 | -55.2% | 16 | -43.8% | |
| Profit before tax | 18 | 20 | -6.7% | 25 | -26.1% |
| Finance costs | 38 | 44 | -11.9% | 40 | -3.6% |
| Depreciation | 68 | 63 | +8.0% | 70 | -3.7% |
| Tax expense | 9 | -1 | n/a | 9 | +7.8% |
| Net profit margin | 1.26% | 3.18% | -1.92 pp | 2.33% | -1.07 pp |
| EPS, basic (₹) | 0.32 | 1.15 | -72.2% | 0.92 | -65.2% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
The company's single operating segment is setting up and managing hospitals and medical diagnostic services. Market value is ₹9,121 crore at the 05 Nov 2026 close of ₹610.90 a share. Net profit for the quarter was ₹9.25 crore, against ₹16.46 crore in the quarter ended 30 Jun 2026.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 401 | 350 | +14.8% | 386 | +3.9% | |
| Revenue from operations | 396 | 344 | +15.0% | 375 | +5.5% |
| Other income | 4 | 4 | +3.4% | 10 | -58.7% |
| -2 | 11 | n/a | 6 | n/a | |
| Profit before tax | -3 | 15 | n/a | 7 | n/a |
| Finance costs | 22 | 21 | +4.2% | 22 | +2.4% |
| Depreciation | 36 | 30 | +18.5% | 40 | -9.7% |
| Tax expense | -1 | 4 | n/a | 2 | n/a |
| Net profit margin | -0.51% | 3.08% | -3.59 pp | 1.44% | -1.95 pp |
| EPS, basic (₹) | -0.14 | 0.77 | n/a | 0.37 | n/a |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
The standalone result moved from profit to loss. Revenue from operations rose 15.0% year on year, to ₹396.04 crore, faster than other income, which rose 3.4%. Profit before tax was a loss of ₹2.93 crore, against a profit of ₹14.60 crore a year earlier, and the company booked a tax credit of ₹0.89 crore.
Depreciation rose 18.5% year on year, to ₹35.74 crore, and finance costs of ₹22.25 crore are 5.5% of total income.
Inference
The filing says the board approved the results at a meeting on 5 Nov 2026, and that the statutory auditor, BSR & Co. LLP, gave an unmodified limited review conclusion on the consolidated results and an unqualified review report on the standalone results.
The filing says that on 5 Oct 2026 Healthcare Global (Kenya) Private Limited acquired 10 more shares of Advanced Molecular Imaging Limited, taking its stake from 50% to 50.10%, and that the joint venture becomes a step-down subsidiary from that date. The effect of this on future results is not stated.
The filing does not say why net profit fell or when the EPCG shortfall will be paid, and the timing and amount of the customs duty payment are not stated.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
